Cytokinetics price target raised to $96 from $87 at Stifel

Stifel analyst James Condulis raised the firm’s price target on Cytokinetics (CYTK) to $96 from $87 and keeps a Buy rating on the shares. The firm thinks ESC was highly bullish for Cytokinetics, reinforcing aficamten’s de-risked, best-in-disease profile in oHCM; and credible optionality in nHCM. For the stock, and even with this morning’s move, Stifel continues to believe the catalyst path ahead remains underappreciated with the oHCM launch where aficamten’s well-positioned to leverage Bristol Myers’ (BMY) extensive market build-out, but with a best-in-class profile; ACACIA-HCM in the first half of 2026, which it thinks likely works; and additional pipeline optionality, including HFpEF. The firm expects shares to work throughout the year as the path forward here becomes better appreciated.